Trinity College Institute of Neuroscience.
Neuropsychiatr Dis Treat. 2011;7:275-92. doi: 10.2147/NDT.S13917. Epub 2011 May 15.
Interferon-α, currently used for the treatment of hepatitis C, is associated with a substantially elevated risk of depression. However, not everyone who takes this drug becomes depressed, so it is important to understand what particular factors may make some individuals more 'at risk' of developing depression than others. Currently there is no consensus as to why interferon-induced depression occurs and the range of putative risk factors is wide and diverse. The identification of risk factors prior to treatment may allow identification of patients who will become depressed on interferon, allowing the possibility of improved treatment support and rates of treatment adherence. Here, we consolidate and review the literature on risk factors, and we discuss the potential confounds within the research examined in order to better isolate the risk factors that may be important in the development of depression in these patients and which might help predict patients likely to become depressed on treatment. We suggest that interactions between psychobehavioral, genetic, and biological risk factors are of particular importance in the occurrence of depression in patients with hepatitis C taking interferon-α.
干扰素-α目前用于治疗丙型肝炎，与抑郁症的风险显著升高有关。然而，并非每个服用这种药物的人都会抑郁，因此了解哪些特定因素可能使某些人比其他人更容易“面临”患上抑郁症的风险是很重要的。目前，干扰素引起的抑郁发生的原因尚无共识，潜在的风险因素范围广泛且多样。在治疗前确定风险因素可能可以识别出在干扰素治疗中会抑郁的患者，从而有可能提供更好的治疗支持和治疗依从率。在这里，我们对风险因素的文献进行了整合和回顾，并讨论了所检查研究中的潜在混杂因素，以便更好地确定在这些患者发生抑郁症的过程中可能重要的风险因素，以及哪些因素可能有助于预测哪些患者在治疗中可能会抑郁。我们认为，在接受干扰素-α治疗的丙型肝炎患者中，心理行为、遗传和生物风险因素之间的相互作用对抑郁症的发生具有特别重要的意义。
